ASX 10 MARCH 2021



CANNTAB GRANTED AUSTRALIAN PATENT

Cann Global (ASX: CGB) ("Cann Global" or the "Company"), is pleased to announce the Australian Patent Office has granted Australian Patent No. AU 2018210690 to its joint venture partner Canntab Therapeutics Limited (CSE: PILL.CN) ("Canntab"), in relation to its proprietary immediate release cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on 22 January 2038.

Canntab is a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications. Canntab now has patent protection in the USA, Canada and Australia for these pills, which protects key features of these unique formulations and positions these products to be a definitive cannabis delivery method amongst established medical professions and the ever expanding number of patients using cannabis for medical purposes.

As previously announced to the market, Cann Global has a 50/50 Joint Venture partnership on hard oral dose cannabinoid tablets with Canntab in Australia. The Company is confident in the demand for these products and placed an initial Canadian \$406,200 (AUD \$418,000) order for six products from the Canntab range including two THC products, two CBD products and two THC/CBD blends. Cann Global has received its import permit for these products, and Canntab will fulfill the order as soon as it receives its export permit from Health Canada.

Cann Global believes these hard pill formulations are unique relative to all other medical CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for a familiar method of taking medications in the form of a pharmaceutical pill, with superior ingredient stability and provide customisable and precise dosing, as opposed to the widely available gel caps and capsule products from other suppliers.

Cann Global will make the products available to patients through the Special Access Scheme B and Authorised prescriber schemes.

As already announced to the market the Canntab products will be made available to the Cannabinoid Medicine Observational Study (CMOS) when received. The study is the largest observational study undertaken in Australia for Cannibinoid Medicine products. CMOS intends to collect data from 20,000 participants nationwide and will assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions.



ABOUT CANN GLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on +61 (0)2 8379 1832, or via email at investorrelations@cannglobal.com.au